Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. [electronic resource]
Producer: 20130604Description: 1426-8 p. digitalISSN:- 1549-490X
- Antibodies, Monoclonal, Humanized -- economics
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Capecitabine
- Colorectal Neoplasms -- drug therapy
- Cost-Benefit Analysis
- Deoxycytidine -- analogs & derivatives
- Fluorouracil -- analogs & derivatives
- Humans
- Induction Chemotherapy
- Leucovorin -- therapeutic use
- Maintenance Chemotherapy
- Neoplasm Metastasis -- drug therapy
- Organoplatinum Compounds -- therapeutic use
- Oxaloacetates
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.